Literature DB >> 33846224

Longitudinal Peripheral Blood Transcriptional Analysis Reveals Molecular Signatures of Disease Progression in COVID-19 Patients.

Qihong Yan1,2, Pingchao Li3, Xianmiao Ye1, Xiaohan Huang1,2, Bo Feng3, Tianxing Ji3, Zhilong Chen4, Feng Li3, Yudi Zhang1,2, Kun Luo1,2, Fengjuan Chen3, Xiaoneng Mo3, Jianhua Wang1, Liqiang Feng1, Fengyu Hu3, Chunliang Lei3, Linbing Qu5, Ling Chen5,3.   

Abstract

Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with some patients developing severe illness or even death. Disease severity has been associated with increased levels of proinflammatory cytokines and lymphopenia. To elucidate the atlas of peripheral immune response and pathways that might lead to immunopathology during COVID-19 disease course, we performed a peripheral blood RNA sequencing analysis of the same patient's samples collected from symptom onset to full recovery. We found that PBMCs at different disease stages exhibited unique transcriptome characteristics. We observed that SARS-CoV-2 infection caused excessive release of inflammatory cytokines and lipid mediators as well as an aberrant increase of low-density neutrophils. Further analysis revealed an increased expression of RNA sensors and robust IFN-stimulated genes expression but a repressed type I IFN production. SARS-CoV-2 infection activated T and B cell responses during the early onset but resulted in transient adaptive immunosuppression during severe disease state. Activation of apoptotic pathways and functional exhaustion may contribute to the reduction of lymphocytes and dysfunction of adaptive immunity, whereas increase in IL2, IL7, and IL15 may facilitate the recovery of the number and function of lymphocytes. Our study provides comprehensive transcriptional signatures of peripheral blood response in patients with moderate COVID-19.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Year:  2021        PMID: 33846224     DOI: 10.4049/jimmunol.2001325

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.

Authors:  Aliakbar Hasankhani; Abolfazl Bahrami; Negin Sheybani; Behzad Aria; Behzad Hemati; Farhang Fatehi; Hamid Ghaem Maghami Farahani; Ghazaleh Javanmard; Mahsa Rezaee; John P Kastelic; Herman W Barkema
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

2.  A multi-tissue study of immune gene expression profiling highlights the key role of the nasal epithelium in COVID-19 severity.

Authors:  Alberto Gómez-Carballa; Irene Rivero-Calle; Jacobo Pardo-Seco; José Gómez-Rial; Carmen Rivero-Velasco; Nuria Rodríguez-Núñez; Gema Barbeito-Castiñeiras; Hugo Pérez-Freixo; Miriam Cebey-López; Ruth Barral-Arca; Carmen Rodriguez-Tenreiro; Ana Dacosta-Urbieta; Xabier Bello; Sara Pischedda; María José Currás-Tuala; Sandra Viz-Lasheras; Federico Martinón-Torres; Antonio Salas
Journal:  Environ Res       Date:  2022-02-22       Impact factor: 8.431

3.  Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module.

Authors:  Hye Kyung Lee; Ludwig Knabl; Ludwig Knabl; Manuel Wieser; Anna Mur; August Zabernigg; Jana Schumacher; Sebastian Kapferer; Norbert Kaiser; Priscilla A Furth; Lothar Hennighausen
Journal:  Sci Rep       Date:  2022-02-18       Impact factor: 4.996

4.  T cell perturbations persist for at least 6 months following hospitalization for COVID-19.

Authors:  Melissa Govender; Francis R Hopkins; Robin Göransson; Cecilia Svanberg; Esaki M Shankar; Maria Hjorth; Åsa Nilsdotter-Augustinsson; Johanna Sjöwall; Sofia Nyström; Marie Larsson
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

Review 5.  Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.

Authors:  Norberto Perico; Monica Cortinovis; Fredy Suter; Giuseppe Remuzzi
Journal:  Lancet Infect Dis       Date:  2022-08-25       Impact factor: 71.421

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.